发明授权
EP1412343B1 COMPOUNDS, WHICH ARE POTENT INHIBITORS OF NA+/CA2+ EXCHANGE MECHANISM AND ARE USEFUL IN THE TREATMENT OF ARRHYTHMIAS
有权
化合物,其中IT是Na + / Ca2 +交换机制的有效抑制剂,以及哪些适合于治疗心律失常
- 专利标题: COMPOUNDS, WHICH ARE POTENT INHIBITORS OF NA+/CA2+ EXCHANGE MECHANISM AND ARE USEFUL IN THE TREATMENT OF ARRHYTHMIAS
- 专利标题(中): 化合物,其中IT是Na + / Ca2 +交换机制的有效抑制剂,以及哪些适合于治疗心律失常
-
申请号: EP02755036.7申请日: 2002-07-10
-
公开(公告)号: EP1412343B1公开(公告)日: 2006-08-30
- 发明人: KOSKELAINEN, Tuula , OTSOMAA, Leena , KARJALAINEN, Arto , KOTOVUORI, Pekka , TENHUNEN, Jukka , RASKU, Sirpa , NORE, Pentti , TIAINEN, Eija , TÖRMÄKANGAS, Olli
- 申请人: Orion Corporation
- 申请人地址: Orionintie 1 02200 Espoo FI
- 专利权人: Orion Corporation
- 当前专利权人: Orion Corporation
- 当前专利权人地址: Orionintie 1 02200 Espoo FI
- 代理机构: Sexton, Jane Helen
- 优先权: FI20011507 20010710
- 国际公布: WO2003006452 20030123
- 主分类号: C07D311/04
- IPC分类号: C07D311/04 ; C07D311/32 ; C07D319/16 ; C07D327/06 ; C07D405/12 ; C07D411/12 ; C07C217/14 ; C07C217/54 ; C07C217/90 ; A61K31/135 ; A61K31/353 ; A61K31/357 ; A61K31/39 ; A61K31/4178 ; A61K31/4433 ; A61P9/06 ; A61P9/10
摘要:
Therapeutically active compounds of formula (I): wherein X is -O-, -CH2- or -C(O)-; Z is -CHR9- or valence bond; Y is -CH2-, -C(O)-, CH(OR10)-, -CH(NR11R12 )-, -O-, -S-, -S(O)- or -S(O2)-, provided that in case Z is a valence bond, Y is not C(O); the dashed line represents an optional double bond in which case Z is -CR9- and Y is -CH-, C(OR10)- or -C(NR11R12 )-; R1 is -(CH2)nNR4R7 or one of the following groups:n is 1 - 4; R2 and R3 are independently H, lower alkyl, lower alkoxy, -NO2, halogen, -CF3, -OH, -NHR8 or -COOH; R4 and R7 are independently H, lower alkyl or lower hydroxyalkyl; R5 is H, lower alkoxy, -CF3, -NH2 or -CN; R6 is -NO2 , -NR14R19, -CF3 or R8 and R16 are independently H or acyl; R9 is H or lower alkyl; R10 is H, alkylsulfonyl or acyl; R11 and R12 are independently H, lower alkyl or acyl; R13 and R18 are independently H or -OR20; R14 and R19 are independently H, acyl, alkylsulfonyl, C(S)NHR17 or C(O)NHR17; R15 is H or NH2; R17 is H or lower alkyl; R20 is H or acyl; and pharmaceutically acceptable salts and esters thereof are disclosed. The compounds are potent inhibitors of Na+/Ca2+ exchange mechanism.
公开/授权文献
信息查询